Search research articles
Contact Us
Filters
Showing results (211-220 of 222) with videos related to
Page
of 23
Sort By:
Canadian Liver Journal
|
December 25, 2023
Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B
Hassan Azhari, Alexandra D Frolkis, Abdel Aziz Shaheen, et al.
Alimentary Pharmacology & Therapeutics
|
October 28, 2020
Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America
Golasa Samadi Kochaksaraei, Eliana Castillo, Matthew D Sadler, et al.
Journal of Hepatology
|
March 25, 2024
Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study
Christina G Plagiannakos, Gideon M Hirschfield, Ellina Lytvyak, et al.
Nature Reviews. Gastroenterology & Hepatology
|
February 19, 2026
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
David E J Jones, Robert Mitchell-Thain, Emma L Culver, et al.
Canadian Liver Journal
|
August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)
Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
Jordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Canadian Liver Journal
|
August 22, 2022
Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant
Victor Dong, Maxime Gosselin, Nishita Jagarlamudi, et al.
Alimentary Pharmacology & Therapeutics
|
October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Journal of Hepatology
|
April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Christopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine
|
November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 222) with videos related to
Sort By:
Page
of 23
Canadian Liver Journal
|
December 25, 2023
Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B
Hassan Azhari, Alexandra D Frolkis, Abdel Aziz Shaheen, et al.
Alimentary Pharmacology & Therapeutics
|
October 28, 2020
Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America
Golasa Samadi Kochaksaraei, Eliana Castillo, Matthew D Sadler, et al.
Journal of Hepatology
|
March 25, 2024
Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study
Christina G Plagiannakos, Gideon M Hirschfield, Ellina Lytvyak, et al.
Nature Reviews. Gastroenterology & Hepatology
|
February 19, 2026
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
David E J Jones, Robert Mitchell-Thain, Emma L Culver, et al.
Canadian Liver Journal
|
August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)
Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
Jordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Canadian Liver Journal
|
August 22, 2022
Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant
Victor Dong, Maxime Gosselin, Nishita Jagarlamudi, et al.
Alimentary Pharmacology & Therapeutics
|
October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Journal of Hepatology
|
April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Christopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
The New England Journal of Medicine
|
November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Page
of 23